Use of KRAS mutation status to predict clinical outcomes in patients with metastatic colorectal cancer (mCRC) treated with the VEGF signaling inhibitor cediranib.
J.M. Jürgensmeier, Jeff Smith, Darrell M. Wilson(Stanford Medicine), Laura A. Pike(Instituto do Câncer do Estado de São Paulo), Sara Morgan, P. M. Hoff, Jane Robertson(Cancer Research UK), Gael McWalter(AstraZeneca (United Kingdom))
Cited by 3
Related Papers
Association of Hypoglycemia, Hyperglycemia, and Glucose Variability With Morbidity and Death in the Pediatric Intensive Care Unit
|PEDIATRICS|2006|359
Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors
|Journal of Clinical Oncology|2007|303
Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
|Gynecologic Oncology|2015|301
Normal ranges for immunochemiluminometric gonadotropin assays
|The Journal of Pediatrics|1995|257
A STUDY OF THE ESTIMATION OF CHLORIDE IN BLOOD AND SERUM
|Journal of Biological Chemistry|1928|234